US20140051173A1 - Analytical devices for detection of low-quality pharmaceuticals - Google Patents

Analytical devices for detection of low-quality pharmaceuticals Download PDF

Info

Publication number
US20140051173A1
US20140051173A1 US13/829,753 US201313829753A US2014051173A1 US 20140051173 A1 US20140051173 A1 US 20140051173A1 US 201313829753 A US201313829753 A US 201313829753A US 2014051173 A1 US2014051173 A1 US 2014051173A1
Authority
US
United States
Prior art keywords
product
pad
chemical components
assay
dietary supplement
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
US13/829,753
Other versions
US9557274B2 (en
Inventor
Toni L. O. Barstis
Mary M. Bevilacqua
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ST MARY'S COLLEGE
Original Assignee
ST MARY'S COLLEGE
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ST MARY'S COLLEGE filed Critical ST MARY'S COLLEGE
Priority to US13/829,753 priority Critical patent/US9557274B2/en
Assigned to ST. MARY'S COLLEGE reassignment ST. MARY'S COLLEGE ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: BARSTIS, TONI L.O., BEVILAQUA, MARY M.
Publication of US20140051173A1 publication Critical patent/US20140051173A1/en
Assigned to ST. MARY'S COLLEGE reassignment ST. MARY'S COLLEGE CORRECTIVE ASSIGNMENT TO CORRECT THE MISSPELLING OF THE 2ND INVENTOR'S LAST NAME FROM "BEVILAQUA" TO --BEVILACQUA-- PREVIOUSLY RECORDED ON REEL 030622 FRAME 0823. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNOR'S INTEREST. Assignors: BARSTIS, TONI L.O., BEVILACQUA, MARY M.
Priority to US15/254,186 priority patent/US10119981B2/en
Application granted granted Critical
Publication of US9557274B2 publication Critical patent/US9557274B2/en
Active legal-status Critical Current
Adjusted expiration legal-status Critical

Links

Images

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/75Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated
    • G01N21/77Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated by observing the effect on a chemical indicator
    • G01N21/78Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated by observing the effect on a chemical indicator producing a change of colour
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/84Systems specially adapted for particular applications
    • G01N21/8483Investigating reagent band
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10TTECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00Chemistry: analytical and immunological testing
    • Y10T436/11Automated chemical analysis

Definitions

  • the invention relates to user-friendly analytical devices, in particular, Paper Analytical Devices (PADs), for detection of at least two chemical components indicative of a low quality pharmaceutical product or dietary supplement, and a method of use thereof.
  • PADs Paper Analytical Devices
  • U.S. Pat. No. 6,136,549 discloses systems for conducting spectrophotometric analysis which includes a chromatographic medium, such as an assay test strip, that is designed to be contacted with a test solution having activated magnetic particles.
  • U.S. Pat. No. 6,770,487 discloses “dip stick” style paper-based diagnostic test devices, in which identifying information and the test result are machine-readable.
  • 6,847,451 discloses apparatuses for determining the concentration of an analyte in a physiological sample, which include at least one light source, a detector array, means for determining whether a sufficient amount of sample is present on each of the plurality of different areas, and means for determining the concentration of the analyte based on the reflected light detected from those areas determined to have sufficient sample
  • U.S. Pat. No. 7,344,081 discloses a method of automatically detecting a test result of a probe zone of a test strip comprising capturing an image of a one-dimensional bar code and an image of at least one test strip from a scanning object, and determining a setting value for the at least one test strip based, at least in part, on said captured image of said bar code.
  • U.S. Pat. No. 7,885,444 discloses a method for determining a response of each probe zone on a test strip by selecting an average pixel value of each section of reference white respectively adjacent to the image of a target line to serve as a reference for determining a color response of the target line.
  • US Publication No. 2008/0012083 discloses an analytical system-on-a-chip that can be used as an analytical imaging device, for example, for detecting the presence of a chemical compound, which may also include software that can detect and analyze the output signals of the device.
  • US Publication No. 2011/0189786 discloses a method of detecting the presence or absence of an analyte in a fluid sample.
  • the method includes applying the sample to an inlet zone of a diagnostic system that includes a hydrophilic cotton loading thread to serve as a capillary to deliver a solute to a reagent testing zone, and detecting color change of reagent analyte interaction.
  • US Publication No. 2011/0111517 discloses a paper-based microfluidic assay device comprising a porous, hydrophilic substrate; a fluid-impermeable barrier defining a boundary of an assay region and a boundary of a main channel region, the main channel region fluidically connected to the assay region; and a strip of conductive material disposed on the porous, hydrophilic substrate for detecting the concentration/flow of analyte.
  • pSiFlow Technology Inc. provides a mobile testing and process management web infrastructure built around its Calibrated Color Match (CCM) image processing technology that enables digital reading of color-based test strips using any mobile phone with a camera.
  • CCM Calibrated Color Match
  • the World Health Organization reports that many medications for sale in underdeveloped countries are of low quality, which either contain low concentrations of active ingredients that are not sufficient to treat the underlying condition, or contain substitute active ingredients that may have adverse effects on some patients, or have no active ingredients at all; or even contain toxic ingredients. Although the prevalence of such medications is difficult to measure, both the WHO and US Food and Drug Administration (FDA) estimate that 10-30% of all drugs in the developing world are low quality drugs. A consumer taking a low quality pharmaceutical product may die or experience other adverse medical effects from the underlying condition or from contaminants in the pharmaceutical product. The failure of treatment may be mistaken for resistant strains of the disease requiring much more rigorous treatment that can itself endanger the patient. Also, low quality medications that fail to cure the underlying condition may speed up development of actual resistance in pathogens.
  • WHO World Health Organization
  • the present invention addresses these needs by providing an inexpensive, user-friendly, consistent analytical device capable of detecting various low quality pharmaceutical products and measuring levels of iodine in iodized salt.
  • the present invention provides an easy-to-use, inexpensive analytical device, typically a Paper Analytical Device (PAD), for detection or analysis of at least two chemical components in a dosage formulation indicative of a low quality pharmaceutical product or dietary supplement.
  • the analytical device typically comprises a multilayer PAD having one or more assay regions of porous, hydrophilic material in communication with a non-chemically interfering binder agent such as parafilm disposed adjacent at least to a hydrophobic layer.
  • Vessels containing reagents are in registry with at least one assay region for which testing for a chemical component is desired. Rupture of a vessel wall establishes communication between corresponding assay regions and the reagent released by the ruptured vessel wall.
  • the vessel may be a separable tubular member insertable between two layers of the PAD.
  • the vessel wall is fabricated from a frangible material.
  • the vessel may be integrally formed within the PAD, with the vessel wall including a rupture zone.
  • the one or more vessels when ruptured are preferably in fluid communication with the assay region, e.g., directly or by a channel or other structure joining the two. In each example, rupture of the vessel wall releases the reagent contained by the vessel wall.
  • a porous, hydrophilic substrate such as a paper may be used for the assay regions.
  • the device includes at least one or more of an information identification zone and a color calibration zone. Alternatively, at least one or more of the information identification zone and the color calibration zone may be integrated within the hydrophobic layer or layers.
  • the device may further include at least one electronically readable information zone that, after activation of the device, provides color information necessary for detection of the chemical components.
  • the electronically readable information zone comprises alignment references for transforming or correcting a captured image of the PAD to facilitate analysis and processing of the color information to more accurately detect the at least two chemical components.
  • the alignment references include a plurality of fiducial markers for orienting the captured image.
  • the chemical components to be detected by the whole PAD include at least one active ingredient and possibly one or more excipients.
  • the active ingredient includes at least one of an anti-malarial, antibiotic, anti-parasitic, cox-inhibitor, analgesic, antipyretic, phosphodiesterase-5 inhibitors, anti-viral, anti-cancer or dietary supplement compound.
  • the color information determines whether an inappropriate combination of active ingredient and excipient is present, indicative of a low quality pharmaceutical or dietary supplement product.
  • the method comprises providing the multilayer analytical device as disclosed herein and disposing the product to be analyzed into assay regions.
  • the device is activated in a manner such that the reagents contact the product to be analyzed in the assay regions to provide color information.
  • vessel rupture may establish communication between a reagent and the corresponding assay region.
  • the activating of the device includes rupturing of the vessel wall sufficiently to enable release of the reagents therein onto the assay regions.
  • the subsequently developed color information is analyzed to detect the presence or absence of the chemical components.
  • kits may be provided for detection of at least two chemical components indicative of a low quality pharmaceutical or dietary supplement product.
  • the kit comprises, but is not limited to, a multilayer analytical device as disclosed herein and instructions for using the kit.
  • the instructions include at least instructions for detecting the presence or absence of the at least two chemical components indicative of a low quality pharmaceutical product or dietary supplement using the kit.
  • the instructions may be provided in hard copy, accessible via a link to a website or mobile application, accessible via a QR code or any combination thereof (including any equivalent and complementary instruction formats).
  • the kit may also include a solvent that is present in an amount sufficient to dilute the pharmaceutical product to be analyzed to an analyzable concentration.
  • PAD as described and shown herein may be provided in singular or plural quantities and may also be provided with one or more other PAD configurations, including, but not limited, to those PAD devices described and shown in co-owned U.S. patent application Ser. No. 13/566,915 and related applications.
  • the PAD disclosed and shown herein is readily used for analyzing the quality of a pharmaceutical or nutritional product, such as an iodized table salt.
  • FIG. 1 shows an exemplary multilayer paper analytical device (PAD).
  • PAD multilayer paper analytical device
  • FIG. 2 shows another exemplary multilayer paper analytical device (PAD).
  • PAD multilayer paper analytical device
  • FIGS. 3 and 3A respectively show operation and assembly of the exemplary multilayer paper analytical device of FIG. 1 .
  • FIG. 4 shows an exemplary Erythromycin PAD.
  • paper analytical device refers to a composition based on a porous hydrophilic material (such as paper) and comprising areas of hydrophobic barriers which define hydrophilic assay areas.
  • the hydrophilic assay areas may include test reagents.
  • low quality pharmaceutical product and “dietary supplement product” refers to products purported to be genuine products for treating a disease or disorder or providing a nutritional supplement but containing low concentrations of active ingredients that are not sufficient to treat purported use, a product containing substitute active ingredients that may have undesired side effects compared to the stated drug, a product containing active ingredients that have undergone degradation, or a product having no active ingredients at all.
  • these terms include products that contain ingredients that should not be present in a genuine product of the stated type including ingredients that may be toxic.
  • active agent refers to a chemical capable of being detected by an analytical device as disclosed herein, such as a PAD.
  • the active agent may include chemically active ingredients, excipients or anticipated degradation products within a pharmaceutical formulation.
  • a “camera device” refers to a device that contains a camera component.
  • Exemplary camera devices are various types of digital cameras and scanners as well as mobile devices such as cell phones, smartphones or similar devices.
  • the images will be uploaded to a computer or other electronic device that is capable of transmitting the pictures to another location.
  • the phone already generally has the ability to forward the image, e.g., as a text message or as part of an e-mail.
  • the present invention provides an easy-to-use, inexpensive analytical device, such as a PAD, for detection of specific chemicals and/or chemical groups in an active ingredient, which is particularly capable of detecting various low quality pharmaceutical and dietary supplement products.
  • a PAD a complex metal-oxide-semiconductor
  • One advantage of the present invention is that more than one active ingredient can be analyzed with the same device, which is especially useful in analyzing a combination drug.
  • binders and fillers that should be present in the stated formulation, e.g., starch as a binder in acetaminophen tablets; and additionally, to screen for a multitude of likely substitute drugs, e.g., an antipyretic in place of expensive anti-malarial drugs, ampicillin in place of erythromycin, and binders or fillers such as gypsum or lactose in place of an active pharmaceutical.
  • the analytical device of the invention comprises a porous, hydrophilic medium, preferably a paper such as a fast chromatography paper or an absorbant blotting paper.
  • a suitable porous hydrophilic medium includes one that has a fast flow rate via capillary action, has enough absorption capacity to hold adequate amounts of reagent; has durability and stability such that it does not fall apart or fall over when wet; and is compatible with at least one of the methods used to fashion assay regions.
  • Characteristics which should be considered when designing an analytical device of the invention, such as a PAD include density, thickness, pH, basis weight, solvent flow-rate through fabricated substrate, compatibility with fabrication methods, pore size, and porosity.
  • suitable materials for an analytical device of the invention include, but are not limited to nitrocellulose acetate, chromatography paper, cellulose acetate, cellulosic paper, filter paper, tissue paper, writing paper, paper towel, cloth, and porous polymer film.
  • the substrate for a PAD is Whatman 3MM Chr chromatography paper, Ahlstrom 205, Ahlstrom 222, Ahlstrom 226, Ahlstrom 319, or Whatman No. 1 filter paper. In one preferred embodiment. Ahlstrom 319 filter paper is used.
  • the final dimension of the PAD can have a length “L”, width “W” and height or depth “H” that can vary, depending on the number and size of assay regions and information zones needed on the PAD.
  • the height or depth is determined by the chemistry required to detect various components of a particular low-quality pharmaceutical or dietary supplement product.
  • assay regions are defined on the analytical device of the invention, either by affixing individual strips or other shapes cut from paper onto an inert backing material, or by patterning a piece of paper with a hydrophobic barrier substantially permeating the thickness of the paper medium to define the boundaries of the desired assay regions.
  • the hydrophilic assay regions or reaction areas with the boundaries defined by the hydrophobic area can be in any suitable size or shape.
  • the precise dimensions of the assay regions are determined by the type of reaction to be performed within each assay region, or for optimizing viewing results.
  • Suitable shapes for reaction areas include rectangular lanes, circles (or “spots”), stars, squares, triangles, etc. Reaction areas can comprise multiple shapes. For example, a rectangular lane may culminate with a circle.
  • each circle can range from about 1.5 cm to about 0.3 cm. Preferably the circles are about 1.0 cm in diameter.
  • the length of rectangular lanes can range from about 1 cm to the full length of the PAD, and the width can range from about 0.1 cm to the full width of the PAD.
  • the assay regions of the PAD can be produced in a number of ways that are known to one skilled in the art.
  • photolithography of a resist such as SU-8 can be used to produce hydrophobic regions within the hydrophilic paper medium according to the procedures laid out in US Publication No. 2011/0111517 A1, which is herein incorporated in its entirety.
  • the PAD can be fabricated using wax printing according to the procedures laid out in Lu, Y.; Shi, W.; Jiang, L.; Qin, J. Lin, B. Electrophoresis 2009, 30, p. 1497-1500 and Carrilho, E.; Martinez, A. W., Whitesides, G. M. Anal. Chem. 2009, 81, p.
  • an HP ColorQube printer is used to deposit wax ink, preferably black, in the desired regions of Ahlstrom 319 paper according to a template laid out in a computer program such as Adobe Illustrator; alternatively, the template may be stored and printed as an image file such as a PDF.
  • the preferred paper type is too thick for wax deposition on one side of the paper to form the necessary continuous hydrophobic barrier, so wax ink must be printed on both sides of the paper, after which the paper is heated to 70-120° C. (preferably 100° C.) to allow the wax to melt through the paper and form a continuous hydrophobic barrier surrounding the desired assay region.
  • a wax crayon can be applied heavily around the regions desired on both the front and back of the paper, after which the paper is heated to 70-120° C. (preferably 100° C.) to allow the wax to melt through the paper and form a continuous hydrophobic barrier surrounding the desired assay region.
  • the “cut and paste” method requires the lanes to be cut from the hydrophilic paper medium and adhered to a relatively strong backing, mylar plastic for example, using an adhesive. This method does not require the application of a hydrophobic agent in order to define the hydrophilic reaction areas. As a result, the chance of bleed-over of hydrophobic agent into the lanes is eliminated.
  • the lanes can be cut using any precise cutter, such as an exacto-knife or craft cutter.
  • an exemplary device 10 that employs the “cut and paste” method is shown as a multilayer device employing a non-chemically interfering binder agent such as parafilm 12 to attach unadulterated test strips 14 to at last one laminate backing 16 (as shown herein, parafilm 12 attaches test strips 14 to first laminate backing 16 a ).
  • a non-chemically interfering binder agent such as parafilm 12 to attach unadulterated test strips 14 to at last one laminate backing 16 (as shown herein, parafilm 12 attaches test strips 14 to first laminate backing 16 a ).
  • One or more vessels 18 are disposed between first and second laminate backings 16 a and 16 b with each vessel having a wall 18 a for containment of an unstable or corrosive reagent 17 therein (see FIGS. 3 and 3A ).
  • Vessels 18 may be independent tubular members as shown that are placed in registry with release openings 20 provided in first laminate backing 16 a and in further registry with corresponding release openings 22 in parafilm 12 .
  • Release openings 20 and 22 are in registry with those test strips 14 for which testing for a particular chemical compound and/or active agent is desired.
  • test strip 14 a may be employed for detecting acetaminophen or vitamin C
  • test strip 14 b may be employed for detecting starch or vitamin C.
  • a substrate 24 which may be a paper layout may be provided between second laminate backing 16 b and a third laminate backing 16 c , which paper layout includes at least one or more of at least one information identification zone (e.g., at least one electronically readable information zone such as a bar code, QR code or set of fiducial marks) and at least one color calibration zone that are readily observed during use of the device.
  • the information identification zone contains information about the PAD-type, serial number and fabrication date and allows for remote identification of the PAD.
  • the color calibration zone allows for accurate computer analysis of PAD images taken under varying light conditions. Fiducial markers aid in orienting captured images so that an image software can correct or transform the captured image.
  • one or more of the information identification zone, the color calibration zone and the fiducial markers may be provided on any of the backings 16 and that these features may be incorporated on separate layers of device 10 to augment the interchangeability of the layers with one another (for example, providing substrate 24 with the fiducial markers and integrating the information identification and color calibration zones on one or more backings 16 ).
  • laminate backings 16 are not limited to the quantity shown, and that fewer or additional laminate backings may be employed as may be amenable for successful testing of detectable chemicals and active agents. It is also understood that the layers shown herein are exemplary, and that the layers may be placed in any order amenable to the successful practice of the device.
  • a related device 10 ′ employs the “cut and paste” method in which the vessels and test strips are integrated with a grate 26 on which a chemical or active agent (e.g., in the form of a pill) may be applied.
  • Grate 26 may comprise emery paper, cardboard or any other suitable material or structure for deriving a suitable testing sample while ensuring a portable and easily stored device.
  • vessel wall 18 may be fabricated from a frangible composite or comparable or equivalent material.
  • vessels 18 are shown herein as independently insertable members, it is understood that one or more vessels may be integrated with one or both of laminate backings 16 a and/or 16 b .
  • laminate backing 16 a or 16 b may be fabricated to include a vessel integral therewith, thereby obviating the need for two laminate backings to house a vessel therebetween.
  • release openings 20 may be replaced by frangible zones (not shown) that are in registry with release openings 22 in parafilm 12 and release reagent 17 upon rupture thereof.
  • one or more insertable vessels may be incorporated with one or more vessels integral with device 10 , which may be desirable when testing of different chemicals will be conducted at different times and/or in different locations. Such a configuration may be desirable when employing different reagents having different storage properties.
  • Vessels 18 stably house those reagents which may degrade over time when exposed to ambient conditions, such that long-term storage is achieved.
  • vessels 18 can be loaded with unstable or corrosive reagents (illustrated generally as reagent 17 ) that are readily released upon compromise of vessel wall 18 a . Because vessels 18 are built into the PAD, they can be broken on-site to release the reagent as needed. Precise lane control as to test strips 14 is thereby maintained while ensuring device requiring minimal packaging and thereby minimal cost.
  • the analytical device also contains at least one assay reagent in each of the assay regions.
  • a hydrophobic barrier defines independent isolated assay regions of various shapes and at least one of the assay regions includes a reagent or precursor thereof that is capable of identifying a component that should not be present in the pharmaceutical product.
  • reagents or regent forming precursors can be optionally loaded into the reaction areas.
  • the reagents or precursors can be loaded into the reaction area individually by hand, or via an automated process.
  • the regents may be pre-loaded as liquid solutions or suspensions or may be loaded into the vessels.
  • Folin-Ciocalteu potassium hexacyano
  • reagents may be deposited from aqueous solution or from organic solution.
  • acetonitrile is the preferred organic solvent because the wax barriers are not affected by the acetonitrile.
  • many colorimetric reagents plateau at particular concentrations so that adding additional reagents will not enhance color results.
  • the upper limit on the amount of reagents added is more or less determined by the PAD's loading capacity.
  • the volume of the reagent loaded onto the PAD can range from about 2 to about 100 microliters, or from about 10 to about 50 microliters, or preferably from about 20 to about 30 microliters.
  • Reagents may be deposited on the surface of the analytical device in many ways that will be familiar to those skilled in the art, including but not limited to the use of: microcapillary pipettes and droppers, single- or multi-channel automatic pipetting devices, rods that can capture a droplet of solution or “frog” type depositors that perform this function with multiple rods simultaneously, dipping or spraying equipment, or solution deposition robots.
  • the invention also provides a method for detecting the presence or absence of a chemical and/or a chemical functional group in a composition, or for quantifying the amount of at least one chemical in a composition, or for comparing the amounts of two chemicals present in the composition.
  • This method comprises providing a paper analytical device of the invention; disposing the composition into the assay region in a manner such that it contacts the assay reagent or reagents in the assay region; and analyzing the assay region to detect the presence or absence of the chemical and/or the chemical functional group in the composition or to detect the amount of the targeted chemical or chemicals present in the assay region or to compare the amounts of two chemicals present in the composition.
  • the chemicals to be detected can be in any suitable formulation, including tablets, pills, solids, or powders.
  • Other suitable formulations include liquids, such as suspensions, syrups, or solutions of medications.
  • a solid formulation can be used directly with the PAD, by swiping or rubbing the formulation onto the PAD at a specific location(s).
  • a solid formulation must be diluted into a liquid solution or suspension in order to be used with the specific PAD.
  • Liquid formulations may be added directly to the PAD, or may be further diluted and then added to the PAD.
  • a formulation may be used both directly and also as a dilution on the same PAD.
  • the PADs can be used to detect low quality human and animal pharmaceutical products, including classes of treating agents such as anti-malarials (artemether, lumifantrine), beta lactam antibiotics (ampicillin, amoxicillin), cox-inhibitors, antiparasitic drugs (albendazole, mebendazole, ivermectin), antipyretics (aspirin, acetaminophen) phosphodiesterase inhibitors (sildenafil citrate), and anti-virals (ostamilvir phosphate). They can also be used to analyze foodstuffs that have been supplemented or fortified with micronutrients (iodine, iron, zinc, vitamin C) or with medications (diethylcarbamazine citrate).
  • NSAIDs ibuprofen
  • analgesics lidocine
  • HMG-CoA reductase inhibitors statins
  • ace-inhibitors quinapril
  • macrolide antibiotics erythromycin
  • anti-anxiety medications alprazolam
  • hi-polar disorder and schizophrenia medications olanzapine
  • anemia medications epoetin alfa
  • anti-retrovirals abacavir
  • a drug tablet may be broken in half and rubbed on the surface of the paper in the assay regions, or a rough surface such as a piece of wire or plastic mesh or sandpaper may be used to assist in forming powdered material on the assay regions.
  • a solid formulation may be crushed or ground to powder, or a capsule containing powdered material may be opened, and the powder may be spread on the assay region using a paddle or spatula.
  • Such deposition of solid material may be carried out with the aid of an assisting device, such as a plastic mesh or plate pierced with holes in regions that correspond to the locations of the assay regions.
  • a straight-edge may be drawn across the top surface of the assisting device to pack the composition within the holes of the assisting device, after which the assisting device is lifted from the PAD.
  • the composition may be disposed within the assay region by placing a solution or suspension containing the composition drop-wise onto the desired region of the paper analytical device.
  • the composition may be disposed within the assay region by dipping part of the PAD into the solution or suspension of the composition and allowing the composition to move into the assay region with the resulting capillary flow.
  • the pharmaceutical product is applied directly to the vessel rupture zones where communication with the reagents forms a solution.
  • the remaining pharmaceutical product is diluted with solvent and dropped onto the other assay regions.
  • the disposing of the solvent into the assay regions typically causes a colorimetric change in each region that can be analyzed to detect the presence/absence of the chemical and/or the chemical functional group in the composition, to quantify the amount of the targeted chemical, or to compare the amounts of two chemicals present in the composition.
  • the hydrophobic regions can also define control regions within the hydrophilic paper medium.
  • a timer region may be included in order to alert the user when the test has completed.
  • the timer region may comprise a color-generating reaction in which one component travels up the lane with the solvent flow and creates a color when it encounters another component at the top of the lane, or it may comprise other timing mechanisms such as delay of the solvent flow by a deposited reagent such as sugars, surfactants, or polymers.
  • the PAD may include positive or negative control regions. A negative control may be included in order to verify that the PAD has not become contaminated during storage or use or that the solvent used to develop the colors does not interfere with a color generating reaction.
  • a positive control may be included to show that the reagents in a test lane are still viable, or it may be used as a standard for the image analysis software as disclosed hereinbelow.
  • the PAD may also contain assay regions whose only function is to demonstrate that the user has complied with instructions for correct use of the PADs, or assay regions whose function is to demonstrate that the PAD is an authentic device and not a counterfeit.
  • the paper analytical device contains at least one electronically readable information zone, which provides information necessary for determining the outcome of the test performed on the PAD based on images obtained by a camera device.
  • the information zone typically includes appropriate information that is electrically readable per se or after being photographed or otherwise imaged electronically.
  • Such information may include an identification tag such as a two-dimensional bar code (e.g., a QR code), color standards, and/or fiducial or alignment marks.
  • Each PAD can be imprinted with a two-dimensional barcode such as a Quick Response (QR) barcode that contains the type and serial number of the PAD so that a PAD test can be uniquely identified and the necessary color processing steps to perform the test can be automatically determined, which provides a simple and inexpensive way to uniquely identify the PAD, in addition to providing pertinent information for perspective distortion correction and subsequent color analysis.
  • QR Quick Response
  • other information can also be encoded in the two-dimensional code image.
  • a key task of the image analysis software is the perspective correction or transformation of distorted images, which transforms an image captured at an unknown standoff and optical axis position to a canonical coordinate system in which regions to be analyzed for subsequent color characterization are expressed.
  • each PAD may also contain one or more additional fiducial markers such as “finder squares” or rectifiers to eliminate angle and 3D distortions of the PAD's photographed image.
  • the identification zone can be placed anywhere on the PAD. Preferably, the identification zone can be printed on the PAD prior to application of hydrophobic regions and the identification zone is located on an upper corner of the PAD.
  • the color content of specific regions of the PAD will be analyzed to automatically determine the test result. This removes human subjectivity in color interpretation.
  • PAD images may be captured under different ambient lighting conditions and their global effect on PAD color distributions must be suppressed.
  • Image analysis software can be used to compare the extracted colors in the PAD image's color calibration zone to known values to identify the specific color correction methods needed.
  • white balancing in which the overall brightness of the image is adjusted to force the white square in the PAD image to have a pure white color value.
  • the calibration zone can be in any suitable shape, including rectangles, squares, circles, or triangles.
  • the sub-regions can be in any suitable shape, including rectangles, squares, circles or triangles.
  • the color calibration zone is a rectangle region and the sub-regions are different colored squares.
  • the color calibration zone can be printed onto the PAD prior to or after application of hydrophobic regions.
  • the calibration zone can be placed anywhere on the PAD.
  • the calibration zone is printed on the PAD prior to application of hydrophobic regions and is located on an upper corner of the PAD.
  • the PAD of the invention comprises one information zone having a color calibration zone, another information zone having multiple fiducial marks, and yet another information zone comprising a QR code or other identification tag.
  • the method further comprises providing a camera device, capturing an image of the PAD that has reacted with the composition using the camera device, and providing an image analysis software capable of using information provided by the information zone and the image of the test result in order to identify and quantify a colorimetric change within the assay region of the paper analytical device shown in the captured image.
  • the capture image contains a two-dimensional bar code such as a QR code and one or more fiducial markers.
  • the image software identifies the QR code region, separates the image of the PAD's assay regions from background present in the picture, scales, rotates, and performs geometrical transformations on the captured PAD image based on the QR code and the one or more fiducial markers, aligns the PAD assay regions with stored images in the database, reads test results from pre-specified locations in the stored assay regions, and classifies the test results.
  • the method of the invention further comprises compiling a database of the captured images of the paper analytical devices and the computed test outcomes, wherein the two-dimensional barcode is a QR code that allows for automated identification of a specific PAD including the PAD-type, serial number and fabrication date.
  • the image analysis software is provided on the camera device for processing the captured image in situ.
  • the image analysis software may be provided on a network server such that the captured image is processed by sending the picture to the network server that performs the analysis and transmits the results back to the camera device.
  • the hydrophobic regions can also define control regions within the hydrophilic paper medium.
  • a timer region may be included in order to alert the user when the test has completed.
  • the time region may comprise a colorimetric indicator.
  • the PAD may include positive or negative control regions.
  • a negative control may be included in order to verify the purity of the reaction solvent.
  • a positive control may be included in order to verify the presence (or absence) of the chemical to be detected.
  • the control substrates if any, may be included in the paper medium at the time the other colorimetric reagents are added to the paper medium.
  • the PAD may also contain hydrophilic regions for titrations and/or reverse titrations, as well as user compliance lanes for improving the accuracy of the quantitative analysis of the chemicals.
  • the PADs may be packaged in kits providing a user with all of the materials necessary for using the PAD.
  • the kit may contain a solvent (such as deionized water or ethanol), a plastic micropipette, weighing paper, and a cotton swab.
  • Instructions may be provided in hard copy, accessible via a link to a website or mobile application, accessible via a QR code or any combination thereof (including any equivalent and complementary instruction formats).
  • the PADs comprising test reagents may be subjected to degradation due to temperature, light, or moisture which may affect the accuracy of the tests performed. As a result, the PADs may be individually packaged and sealed in light- and moisture-resistant packets.
  • the packets may be packaged with a desiccant in order to maintain a specific moisture level, and remove excess moisture.
  • a kit for detecting the presence/absence of a chemical and/or a chemical functional group in a composition, quantifying a chemical in a composition, or measuring the relative amounts of two materials present in a composition includes a PAD as disclosed herein; a solvent sufficient to saturate the paper assay device; and instructions for detecting the presence/absence of a chemical and/or a chemical functional group in a composition, quantifying a chemical in a composition, or measuring the relative amounts of two materials present in a composition.
  • the solvent is one that is sufficient to dissolve or suspend the composition containing the chemical and/or the chemical functional group to be analyzed.
  • the kit contains a dish to hold the solvent and a spatula swab, or pipette for applying the composition onto the PAD.
  • FIG. 4 shows an exemplary embodiment of an Erythromycin PAD 30 comprising a color calibration zone 32 , an identification zone 34 , reaction areas as well as a timer region.
  • PAD 30 includes a “red flag” wheel 36 having a plurality of spokes 36 a wherein each spoke is customizable with different chemicals to test for unique excipients and counterfeiting agents. The specific type of chemical in each spoke can be selected depending upon where the test is being conducted as well as to anticipate the types of counterfeit drugs that may be in use in such areas.
  • Reaction areas 38 , 40 , 42 , 44 , 46 and 48 work in concert to perform a quantitative and qualitative assessment of the active ingredient and possible counterfeiting agents.
  • HCl and Bromocresol green at area 38 works in conjunction with HCl and Methyl yellow at area 40 to help determine the concentration of Erythromycin.
  • Ninhydrin at area 42 detects counterfeiting agents with primary or secondary amines.
  • Sodium nitroprusside-acetylaldehyde at area 44 detects the presence of amines and counterfeiting agents.
  • phenol treated paper over a capillary containing sulfuric acid detects and differentiates between certain reducing sugars when activated colorimetrically.
  • ferric iron in glacial acetic acid and concentrated sulfuric acid contained in a glass capillary under glass fiber paper, detects the presence of macrolide rings when activated. It is understood that testing is not constrained by the examples disclosed herein. For instance, wheel 36 and spokes 36 a thereof may be customizable along with the reaction areas to proactively combat changes in counterfeiting efforts. As counterfeiters recognize the testing patters of a PAD 30 and alter their products according, PAD 30 can be customized with alternative testing reagents in anticipation of the alteration of counterfeit products.
  • the color changes of the PAD regions of interest are identified to determine a qualitative or qualitative test result. While the precise amount of active agent may not be identified, the brightness or intensity of the assaying region can provide some indication of the relative amount of active agent that is present in the product tested.
  • the PADs are developed as business-card sized testing systems that can help determine the authenticity of a suspicious pharmaceutical. Paper, or another absorbant material, is impregnated with a colorimetric reagent(s) that will indicate when a particular chemical or functional group is present.
  • the assay regions of the PAD were produced in a number of ways that are known to one skilled in the art:
  • the paper medium is saturated with a crosslinking photoresist and then exposed to UV radiation in a pattern, creating hydrophobic and hydrophilic zones thereby.
  • a modified inkjet printer places hydrophobic barriers of black wax to create lanes. The PAD is then heated to ensure full permeation through the paper.
  • the multilayer cut and paste design uses parafilm to attach unadulterated test strips to a laminate backing (e.g., as shown and described herein with respect to FIG. 1 ).
  • Capillaries are loaded with unstable or corrosive reagents that are built into the PAD so that they can be broken on-site to release the reagent (e.g., as shown and described herein with respect to FIGS. 3 and 3A ).
  • Cost of reagents and labor were assumed to be approximately equal and therefore ignored for the purposes of this analysis.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Plasma & Fusion (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)

Abstract

A multilayer Paper Analytical Device (PAD) is provided for detection of at least two chemical components indicative of a low quality pharmaceutical or dietary supplement product. A method for detection of at least two chemical components indicative of a low quality pharmaceutical or dietary supplement product is also provided that employs a multilayer PAD. A kit is provided for detection of at least two chemical components indicative of a low quality pharmaceutical or dietary supplement product that includes a multilayer PAD and instructions for using the kit.

Description

    FIELD OF THE INVENTION
  • The invention relates to user-friendly analytical devices, in particular, Paper Analytical Devices (PADs), for detection of at least two chemical components indicative of a low quality pharmaceutical product or dietary supplement, and a method of use thereof.
  • BACKGROUND OF THE INVENTION
  • User-friendly analytical devices such as Paper Analytical Devices (PADs) are known in the art as convenient and inexpensive means for assaying chemicals. As these devices contain all necessary reagents and do not require power, they are easy to operate in a field setting. U.S. Pat. No. 6,136,549 discloses systems for conducting spectrophotometric analysis which includes a chromatographic medium, such as an assay test strip, that is designed to be contacted with a test solution having activated magnetic particles. U.S. Pat. No. 6,770,487 discloses “dip stick” style paper-based diagnostic test devices, in which identifying information and the test result are machine-readable. U.S. Pat. No. 6,847,451 discloses apparatuses for determining the concentration of an analyte in a physiological sample, which include at least one light source, a detector array, means for determining whether a sufficient amount of sample is present on each of the plurality of different areas, and means for determining the concentration of the analyte based on the reflected light detected from those areas determined to have sufficient sample, U.S. Pat. No. 7,344,081 discloses a method of automatically detecting a test result of a probe zone of a test strip comprising capturing an image of a one-dimensional bar code and an image of at least one test strip from a scanning object, and determining a setting value for the at least one test strip based, at least in part, on said captured image of said bar code. U.S. Pat. No. 7,885,444 discloses a method for determining a response of each probe zone on a test strip by selecting an average pixel value of each section of reference white respectively adjacent to the image of a target line to serve as a reference for determining a color response of the target line. US Publication No. 2008/0012083 discloses an analytical system-on-a-chip that can be used as an analytical imaging device, for example, for detecting the presence of a chemical compound, which may also include software that can detect and analyze the output signals of the device. US Publication No. 2011/0189786 discloses a method of detecting the presence or absence of an analyte in a fluid sample. The method includes applying the sample to an inlet zone of a diagnostic system that includes a hydrophilic cotton loading thread to serve as a capillary to deliver a solute to a reagent testing zone, and detecting color change of reagent analyte interaction. US Publication No. 2011/0111517 discloses a paper-based microfluidic assay device comprising a porous, hydrophilic substrate; a fluid-impermeable barrier defining a boundary of an assay region and a boundary of a main channel region, the main channel region fluidically connected to the assay region; and a strip of conductive material disposed on the porous, hydrophilic substrate for detecting the concentration/flow of analyte. In a commercial embodiment, pSiFlow Technology Inc. provides a mobile testing and process management web infrastructure built around its Calibrated Color Match (CCM) image processing technology that enables digital reading of color-based test strips using any mobile phone with a camera.
  • The World Health Organization (WHO) reports that many medications for sale in underdeveloped countries are of low quality, which either contain low concentrations of active ingredients that are not sufficient to treat the underlying condition, or contain substitute active ingredients that may have adverse effects on some patients, or have no active ingredients at all; or even contain toxic ingredients. Although the prevalence of such medications is difficult to measure, both the WHO and US Food and Drug Administration (FDA) estimate that 10-30% of all drugs in the developing world are low quality drugs. A consumer taking a low quality pharmaceutical product may die or experience other adverse medical effects from the underlying condition or from contaminants in the pharmaceutical product. The failure of treatment may be mistaken for resistant strains of the disease requiring much more rigorous treatment that can itself endanger the patient. Also, low quality medications that fail to cure the underlying condition may speed up development of actual resistance in pathogens.
  • Multiple factors contribute to the prevalence of low quality pharmaceutical products in developing countries. First of all, manufacturing and selling low quality pharmaceutical products are both easy and hugely lucrative, and low quality products can enter the supply chain at many points. Moreover, buyers and consumers cannot assess identity or quality of pharmaceutical products. Furthermore, manufacturing low quality pharmaceutical products is not a serious crime in many countries, and there is a low risk of detection from official agencies and organizations. Finally, the time, expertise, and expense required for testing pharmaceutical products is a particular barrier to effective post-market surveillance of pharmaceuticals in developing countries.
  • Some medical conditions arise not from a pathogen, but from a deficiency in an essential nutrient. For example, widespread iodine deficiency is a problem in many underdeveloped countries that is associated with developmental impairment in children. Fortification of table salt with potassium iodate or potassium iodide is a common route to address this problem. However, production and distribution methods for iodized table salt in many developing countries yield inadequate or inconsistent levels of iodine. Unfortunately, the time and expense of testing for iodized table salt deters manufacturers, distributors, and end-users from testing iodized table salt to determine iodine concentrations. Thus, a low-cost method of testing iodized table salt at the production facility or in the field is needed to determine whether the salt is adequately fortified with iodine within therapeutic concentrations recommended by the WHO.
  • Thus, there exist long-felt needs for a low-cost, easy-to-use, reliable, minimalistic chemical means of detecting low quality pharmaceutical products and dietary supplements such as iodized salt. These quality problems are also present for veterinary medications and nutritional supplements for animals. The present invention addresses these needs by providing an inexpensive, user-friendly, consistent analytical device capable of detecting various low quality pharmaceutical products and measuring levels of iodine in iodized salt.
  • SUMMARY OF THE INVENTION
  • The present invention provides an easy-to-use, inexpensive analytical device, typically a Paper Analytical Device (PAD), for detection or analysis of at least two chemical components in a dosage formulation indicative of a low quality pharmaceutical product or dietary supplement. The analytical device typically comprises a multilayer PAD having one or more assay regions of porous, hydrophilic material in communication with a non-chemically interfering binder agent such as parafilm disposed adjacent at least to a hydrophobic layer. Vessels containing reagents are in registry with at least one assay region for which testing for a chemical component is desired. Rupture of a vessel wall establishes communication between corresponding assay regions and the reagent released by the ruptured vessel wall.
  • The vessel may be a separable tubular member insertable between two layers of the PAD. In this exemplary embodiment, the vessel wall is fabricated from a frangible material. Alternatively, the vessel may be integrally formed within the PAD, with the vessel wall including a rupture zone. The one or more vessels when ruptured are preferably in fluid communication with the assay region, e.g., directly or by a channel or other structure joining the two. In each example, rupture of the vessel wall releases the reagent contained by the vessel wall.
  • A porous, hydrophilic substrate such as a paper may be used for the assay regions. The device includes at least one or more of an information identification zone and a color calibration zone. Alternatively, at least one or more of the information identification zone and the color calibration zone may be integrated within the hydrophobic layer or layers.
  • The device may further include at least one electronically readable information zone that, after activation of the device, provides color information necessary for detection of the chemical components. The electronically readable information zone comprises alignment references for transforming or correcting a captured image of the PAD to facilitate analysis and processing of the color information to more accurately detect the at least two chemical components. The alignment references include a plurality of fiducial markers for orienting the captured image.
  • The chemical components to be detected by the whole PAD include at least one active ingredient and possibly one or more excipients. The active ingredient includes at least one of an anti-malarial, antibiotic, anti-parasitic, cox-inhibitor, analgesic, antipyretic, phosphodiesterase-5 inhibitors, anti-viral, anti-cancer or dietary supplement compound. The color information determines whether an inappropriate combination of active ingredient and excipient is present, indicative of a low quality pharmaceutical or dietary supplement product.
  • Also provided is a method for detection of at least two chemical components indicative of a low quality pharmaceutical or dietary supplement product. The method comprises providing the multilayer analytical device as disclosed herein and disposing the product to be analyzed into assay regions. The device is activated in a manner such that the reagents contact the product to be analyzed in the assay regions to provide color information. In some cases, vessel rupture may establish communication between a reagent and the corresponding assay region. Generally, the activating of the device includes rupturing of the vessel wall sufficiently to enable release of the reagents therein onto the assay regions. The subsequently developed color information is analyzed to detect the presence or absence of the chemical components.
  • Additionally, a kit may be provided for detection of at least two chemical components indicative of a low quality pharmaceutical or dietary supplement product. The kit comprises, but is not limited to, a multilayer analytical device as disclosed herein and instructions for using the kit. The instructions include at least instructions for detecting the presence or absence of the at least two chemical components indicative of a low quality pharmaceutical product or dietary supplement using the kit. The instructions may be provided in hard copy, accessible via a link to a website or mobile application, accessible via a QR code or any combination thereof (including any equivalent and complementary instruction formats). The kit may also include a solvent that is present in an amount sufficient to dilute the pharmaceutical product to be analyzed to an analyzable concentration.
  • The PAD as described and shown herein may be provided in singular or plural quantities and may also be provided with one or more other PAD configurations, including, but not limited, to those PAD devices described and shown in co-owned U.S. patent application Ser. No. 13/566,915 and related applications.
  • The PAD disclosed and shown herein is readily used for analyzing the quality of a pharmaceutical or nutritional product, such as an iodized table salt.
  • BRIEF DESCRIPTION OF THE DRAWINGS
  • Further features of the invention, its nature and various advantages will be more apparent from the following detailed description, taken in conjunction with the accompanying drawings in which like reference characters refer to like parts throughout and in which:
  • FIG. 1 shows an exemplary multilayer paper analytical device (PAD).
  • FIG. 2 shows another exemplary multilayer paper analytical device (PAD).
  • FIGS. 3 and 3A respectively show operation and assembly of the exemplary multilayer paper analytical device of FIG. 1.
  • FIG. 4 shows an exemplary Erythromycin PAD.
  • DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
  • As used herein, “paper analytical device” (or “PAD”) refers to a composition based on a porous hydrophilic material (such as paper) and comprising areas of hydrophobic barriers which define hydrophilic assay areas. The hydrophilic assay areas may include test reagents.
  • As used herein, “low quality pharmaceutical product” and “dietary supplement product” refers to products purported to be genuine products for treating a disease or disorder or providing a nutritional supplement but containing low concentrations of active ingredients that are not sufficient to treat purported use, a product containing substitute active ingredients that may have undesired side effects compared to the stated drug, a product containing active ingredients that have undergone degradation, or a product having no active ingredients at all. In addition, these terms include products that contain ingredients that should not be present in a genuine product of the stated type including ingredients that may be toxic.
  • As used herein, “active agent” refers to a chemical capable of being detected by an analytical device as disclosed herein, such as a PAD. The active agent may include chemically active ingredients, excipients or anticipated degradation products within a pharmaceutical formulation.
  • As used herein, a “camera device” refers to a device that contains a camera component. Exemplary camera devices are various types of digital cameras and scanners as well as mobile devices such as cell phones, smartphones or similar devices. When digital cameras are used, the images will be uploaded to a computer or other electronic device that is capable of transmitting the pictures to another location. Of course, when a picture or image is taken from a mobile phone, the phone already generally has the ability to forward the image, e.g., as a text message or as part of an e-mail.
  • The present invention provides an easy-to-use, inexpensive analytical device, such as a PAD, for detection of specific chemicals and/or chemical groups in an active ingredient, which is particularly capable of detecting various low quality pharmaceutical and dietary supplement products. One advantage of the present invention is that more than one active ingredient can be analyzed with the same device, which is especially useful in analyzing a combination drug. Moreover, in addition to verification of an appropriate active ingredient that should be present, it is also possible to screen for binders and fillers that should be present in the stated formulation, e.g., starch as a binder in acetaminophen tablets; and additionally, to screen for a multitude of likely substitute drugs, e.g., an antipyretic in place of expensive anti-malarial drugs, ampicillin in place of erythromycin, and binders or fillers such as gypsum or lactose in place of an active pharmaceutical.
  • Porous Hydrophilic Substrate
  • Typically, the analytical device of the invention comprises a porous, hydrophilic medium, preferably a paper such as a fast chromatography paper or an absorbant blotting paper. A suitable porous hydrophilic medium includes one that has a fast flow rate via capillary action, has enough absorption capacity to hold adequate amounts of reagent; has durability and stability such that it does not fall apart or fall over when wet; and is compatible with at least one of the methods used to fashion assay regions. Characteristics which should be considered when designing an analytical device of the invention, such as a PAD, include density, thickness, pH, basis weight, solvent flow-rate through fabricated substrate, compatibility with fabrication methods, pore size, and porosity. Examples of suitable materials for an analytical device of the invention, such as a PAD, include, but are not limited to nitrocellulose acetate, chromatography paper, cellulose acetate, cellulosic paper, filter paper, tissue paper, writing paper, paper towel, cloth, and porous polymer film. In one embodiment, the substrate for a PAD is Whatman 3MM Chr chromatography paper, Ahlstrom 205, Ahlstrom 222, Ahlstrom 226, Ahlstrom 319, or Whatman No. 1 filter paper. In one preferred embodiment. Ahlstrom 319 filter paper is used.
  • Fabrication of the PAD and Assay Regions Thereupon
  • The final dimension of the PAD can have a length “L”, width “W” and height or depth “H” that can vary, depending on the number and size of assay regions and information zones needed on the PAD. The height or depth is determined by the chemistry required to detect various components of a particular low-quality pharmaceutical or dietary supplement product.
  • Several assay regions are defined on the analytical device of the invention, either by affixing individual strips or other shapes cut from paper onto an inert backing material, or by patterning a piece of paper with a hydrophobic barrier substantially permeating the thickness of the paper medium to define the boundaries of the desired assay regions. The hydrophilic assay regions or reaction areas with the boundaries defined by the hydrophobic area can be in any suitable size or shape. The precise dimensions of the assay regions are determined by the type of reaction to be performed within each assay region, or for optimizing viewing results. Suitable shapes for reaction areas include rectangular lanes, circles (or “spots”), stars, squares, triangles, etc. Reaction areas can comprise multiple shapes. For example, a rectangular lane may culminate with a circle. The diameter of each circle can range from about 1.5 cm to about 0.3 cm. Preferably the circles are about 1.0 cm in diameter. The length of rectangular lanes can range from about 1 cm to the full length of the PAD, and the width can range from about 0.1 cm to the full width of the PAD.
  • The assay regions of the PAD can be produced in a number of ways that are known to one skilled in the art. For example, photolithography of a resist such as SU-8 can be used to produce hydrophobic regions within the hydrophilic paper medium according to the procedures laid out in US Publication No. 2011/0111517 A1, which is herein incorporated in its entirety. Alternately, the PAD can be fabricated using wax printing according to the procedures laid out in Lu, Y.; Shi, W.; Jiang, L.; Qin, J. Lin, B. Electrophoresis 2009, 30, p. 1497-1500 and Carrilho, E.; Martinez, A. W., Whitesides, G. M. Anal. Chem. 2009, 81, p. 7091-7095, which are herein incorporated in their entireties. In a preferred embodiment, an HP ColorQube printer is used to deposit wax ink, preferably black, in the desired regions of Ahlstrom 319 paper according to a template laid out in a computer program such as Adobe Illustrator; alternatively, the template may be stored and printed as an image file such as a PDF. The preferred paper type is too thick for wax deposition on one side of the paper to form the necessary continuous hydrophobic barrier, so wax ink must be printed on both sides of the paper, after which the paper is heated to 70-120° C. (preferably 100° C.) to allow the wax to melt through the paper and form a continuous hydrophobic barrier surrounding the desired assay region. For prototyping, a wax crayon can be applied heavily around the regions desired on both the front and back of the paper, after which the paper is heated to 70-120° C. (preferably 100° C.) to allow the wax to melt through the paper and form a continuous hydrophobic barrier surrounding the desired assay region.
  • The “cut and paste” method requires the lanes to be cut from the hydrophilic paper medium and adhered to a relatively strong backing, mylar plastic for example, using an adhesive. This method does not require the application of a hydrophobic agent in order to define the hydrophilic reaction areas. As a result, the chance of bleed-over of hydrophobic agent into the lanes is eliminated. The lanes can be cut using any precise cutter, such as an exacto-knife or craft cutter.
  • Referring to FIG. 1, an exemplary device 10 that employs the “cut and paste” method is shown as a multilayer device employing a non-chemically interfering binder agent such as parafilm 12 to attach unadulterated test strips 14 to at last one laminate backing 16 (as shown herein, parafilm 12 attaches test strips 14 to first laminate backing 16 a). One or more vessels 18 are disposed between first and second laminate backings 16 a and 16 b with each vessel having a wall 18 a for containment of an unstable or corrosive reagent 17 therein (see FIGS. 3 and 3A). Vessels 18 may be independent tubular members as shown that are placed in registry with release openings 20 provided in first laminate backing 16 a and in further registry with corresponding release openings 22 in parafilm 12. Release openings 20 and 22 are in registry with those test strips 14 for which testing for a particular chemical compound and/or active agent is desired. For example, test strip 14 a may be employed for detecting acetaminophen or vitamin C, while test strip 14 b may be employed for detecting starch or vitamin C.
  • A substrate 24 which may be a paper layout may be provided between second laminate backing 16 b and a third laminate backing 16 c, which paper layout includes at least one or more of at least one information identification zone (e.g., at least one electronically readable information zone such as a bar code, QR code or set of fiducial marks) and at least one color calibration zone that are readily observed during use of the device. The information identification zone contains information about the PAD-type, serial number and fabrication date and allows for remote identification of the PAD. The color calibration zone allows for accurate computer analysis of PAD images taken under varying light conditions. Fiducial markers aid in orienting captured images so that an image software can correct or transform the captured image. It is understood that one or more of the information identification zone, the color calibration zone and the fiducial markers may be provided on any of the backings 16 and that these features may be incorporated on separate layers of device 10 to augment the interchangeability of the layers with one another (for example, providing substrate 24 with the fiducial markers and integrating the information identification and color calibration zones on one or more backings 16).
  • It is understood that laminate backings 16 are not limited to the quantity shown, and that fewer or additional laminate backings may be employed as may be amenable for successful testing of detectable chemicals and active agents. It is also understood that the layers shown herein are exemplary, and that the layers may be placed in any order amenable to the successful practice of the device.
  • Referring further to FIG. 2, a related device 10′ employs the “cut and paste” method in which the vessels and test strips are integrated with a grate 26 on which a chemical or active agent (e.g., in the form of a pill) may be applied. Grate 26 may comprise emery paper, cardboard or any other suitable material or structure for deriving a suitable testing sample while ensuring a portable and easily stored device.
  • When vessels 18 are independent members insertable between laminate backings 16 a and 16 b, vessel wall 18 may be fabricated from a frangible composite or comparable or equivalent material. Although vessels 18 are shown herein as independently insertable members, it is understood that one or more vessels may be integrated with one or both of laminate backings 16 a and/or 16 b. For example, either laminate backing 16 a or 16 b may be fabricated to include a vessel integral therewith, thereby obviating the need for two laminate backings to house a vessel therebetween. In this example, release openings 20 may be replaced by frangible zones (not shown) that are in registry with release openings 22 in parafilm 12 and release reagent 17 upon rupture thereof. Also, one or more insertable vessels may be incorporated with one or more vessels integral with device 10, which may be desirable when testing of different chemicals will be conducted at different times and/or in different locations. Such a configuration may be desirable when employing different reagents having different storage properties.
  • Vessels 18 stably house those reagents which may degrade over time when exposed to ambient conditions, such that long-term storage is achieved. Referring further to FIGS. 3 and 3A, vessels 18 can be loaded with unstable or corrosive reagents (illustrated generally as reagent 17) that are readily released upon compromise of vessel wall 18 a. Because vessels 18 are built into the PAD, they can be broken on-site to release the reagent as needed. Precise lane control as to test strips 14 is thereby maintained while ensuring device requiring minimal packaging and thereby minimal cost.
  • Reagents and Reagent Deposition
  • The analytical device also contains at least one assay reagent in each of the assay regions. In one embodiment, a hydrophobic barrier defines independent isolated assay regions of various shapes and at least one of the assay regions includes a reagent or precursor thereof that is capable of identifying a component that should not be present in the pharmaceutical product.
  • Various reagents or regent forming precursors can be optionally loaded into the reaction areas. The reagents or precursors can be loaded into the reaction area individually by hand, or via an automated process. The regents may be pre-loaded as liquid solutions or suspensions or may be loaded into the vessels. Examples of reagent materials suitable for use in the analytical device of invention such as a PAD include, but are not limited to, Folin-Ciocalteu, potassium hexacyanoferrate(II) trihydrate, iodine-potassium iodide reagent, universal indicator, ferric chloride, triiodide, triiodide-starch complex, soluble starch; cationic, anionic, and neutral pH indicators; barium chloride, sodium rhodizonate, potassium hexacyanoferrate(II), NaOH, tosic acid, potassium carbonate, citric acid, copper sulfate, sodium tetraphenylborate, cobalt thiocyanate, ammonium molybdate, nitroaniline, 1,2-napthaquinone-4-sulfonate, dimethylglyoxime, and paradimethylaminobenzaldehyde. These reagents may be deposited from aqueous solution or from organic solution. For wax printed PADs, acetonitrile is the preferred organic solvent because the wax barriers are not affected by the acetonitrile. Surprisingly, many colorimetric reagents plateau at particular concentrations so that adding additional reagents will not enhance color results. Thus, the upper limit on the amount of reagents added is more or less determined by the PAD's loading capacity. The volume of the reagent loaded onto the PAD can range from about 2 to about 100 microliters, or from about 10 to about 50 microliters, or preferably from about 20 to about 30 microliters.
  • Reagents may be deposited on the surface of the analytical device in many ways that will be familiar to those skilled in the art, including but not limited to the use of: microcapillary pipettes and droppers, single- or multi-channel automatic pipetting devices, rods that can capture a droplet of solution or “frog” type depositors that perform this function with multiple rods simultaneously, dipping or spraying equipment, or solution deposition robots.
  • General Method of Use
  • The invention also provides a method for detecting the presence or absence of a chemical and/or a chemical functional group in a composition, or for quantifying the amount of at least one chemical in a composition, or for comparing the amounts of two chemicals present in the composition. This method comprises providing a paper analytical device of the invention; disposing the composition into the assay region in a manner such that it contacts the assay reagent or reagents in the assay region; and analyzing the assay region to detect the presence or absence of the chemical and/or the chemical functional group in the composition or to detect the amount of the targeted chemical or chemicals present in the assay region or to compare the amounts of two chemicals present in the composition.
  • Compositions Suitable for Analysis
  • The chemicals to be detected can be in any suitable formulation, including tablets, pills, solids, or powders. Other suitable formulations include liquids, such as suspensions, syrups, or solutions of medications. In some instances, a solid formulation can be used directly with the PAD, by swiping or rubbing the formulation onto the PAD at a specific location(s). In other instances, a solid formulation must be diluted into a liquid solution or suspension in order to be used with the specific PAD. Liquid formulations may be added directly to the PAD, or may be further diluted and then added to the PAD. In some instances, a formulation may be used both directly and also as a dilution on the same PAD.
  • The PADs can be used to detect low quality human and animal pharmaceutical products, including classes of treating agents such as anti-malarials (artemether, lumifantrine), beta lactam antibiotics (ampicillin, amoxicillin), cox-inhibitors, antiparasitic drugs (albendazole, mebendazole, ivermectin), antipyretics (aspirin, acetaminophen) phosphodiesterase inhibitors (sildenafil citrate), and anti-virals (ostamilvir phosphate). They can also be used to analyze foodstuffs that have been supplemented or fortified with micronutrients (iodine, iron, zinc, vitamin C) or with medications (diethylcarbamazine citrate). However, other classes of active agents are also contemplated, such as NSAIDs (ibuprofen), analgesics (lidocine), HMG-CoA reductase inhibitors (statins), ace-inhibitors (quinapril), macrolide antibiotics (erythromycin), anti-anxiety medications (alprazolam), hi-polar disorder and schizophrenia medications (olanzapine), anemia medications (epoetin alfa), and anti-retrovirals (abacavir), etc. Specific PADs and their application are disclosed herein.
  • Deposition of the Composition to be Analyzed on the PAD and Activation of the PAD Tests
  • In one embodiment, a drug tablet may be broken in half and rubbed on the surface of the paper in the assay regions, or a rough surface such as a piece of wire or plastic mesh or sandpaper may be used to assist in forming powdered material on the assay regions. Alternatively, a solid formulation may be crushed or ground to powder, or a capsule containing powdered material may be opened, and the powder may be spread on the assay region using a paddle or spatula. Such deposition of solid material may be carried out with the aid of an assisting device, such as a plastic mesh or plate pierced with holes in regions that correspond to the locations of the assay regions. In order to deposit a controlled amount of the composition to be analyzed, a straight-edge may be drawn across the top surface of the assisting device to pack the composition within the holes of the assisting device, after which the assisting device is lifted from the PAD. The composition may be disposed within the assay region by placing a solution or suspension containing the composition drop-wise onto the desired region of the paper analytical device. Alternatively, the composition may be disposed within the assay region by dipping part of the PAD into the solution or suspension of the composition and allowing the composition to move into the assay region with the resulting capillary flow.
  • In the preferred embodiment, the pharmaceutical product is applied directly to the vessel rupture zones where communication with the reagents forms a solution. The remaining pharmaceutical product is diluted with solvent and dropped onto the other assay regions.
  • General Method of Analysis of the Test Results
  • Once the composition has been applied to the assay regions, the disposing of the solvent into the assay regions typically causes a colorimetric change in each region that can be analyzed to detect the presence/absence of the chemical and/or the chemical functional group in the composition, to quantify the amount of the targeted chemical, or to compare the amounts of two chemicals present in the composition.
  • The hydrophobic regions can also define control regions within the hydrophilic paper medium. For example, a timer region may be included in order to alert the user when the test has completed. The timer region may comprise a color-generating reaction in which one component travels up the lane with the solvent flow and creates a color when it encounters another component at the top of the lane, or it may comprise other timing mechanisms such as delay of the solvent flow by a deposited reagent such as sugars, surfactants, or polymers. Additionally, the PAD may include positive or negative control regions. A negative control may be included in order to verify that the PAD has not become contaminated during storage or use or that the solvent used to develop the colors does not interfere with a color generating reaction. A positive control may be included to show that the reagents in a test lane are still viable, or it may be used as a standard for the image analysis software as disclosed hereinbelow. The PAD may also contain assay regions whose only function is to demonstrate that the user has complied with instructions for correct use of the PADs, or assay regions whose function is to demonstrate that the PAD is an authentic device and not a counterfeit.
  • Information Identification Zone
  • The paper analytical device contains at least one electronically readable information zone, which provides information necessary for determining the outcome of the test performed on the PAD based on images obtained by a camera device. The information zone typically includes appropriate information that is electrically readable per se or after being photographed or otherwise imaged electronically. Such information may include an identification tag such as a two-dimensional bar code (e.g., a QR code), color standards, and/or fiducial or alignment marks.
  • Each PAD can be imprinted with a two-dimensional barcode such as a Quick Response (QR) barcode that contains the type and serial number of the PAD so that a PAD test can be uniquely identified and the necessary color processing steps to perform the test can be automatically determined, which provides a simple and inexpensive way to uniquely identify the PAD, in addition to providing pertinent information for perspective distortion correction and subsequent color analysis. Depending on the application, other information can also be encoded in the two-dimensional code image. A key task of the image analysis software is the perspective correction or transformation of distorted images, which transforms an image captured at an unknown standoff and optical axis position to a canonical coordinate system in which regions to be analyzed for subsequent color characterization are expressed. The origin and basis vectors for this coordinate system can be automatically calculated from the position of “finder marks” or fiducial marks on the QR code. In some embodiments, each PAD may also contain one or more additional fiducial markers such as “finder squares” or rectifiers to eliminate angle and 3D distortions of the PAD's photographed image. The identification zone can be placed anywhere on the PAD. Preferably, the identification zone can be printed on the PAD prior to application of hydrophobic regions and the identification zone is located on an upper corner of the PAD.
  • Color Calibration Zone
  • In analyzing a PAD, the color content of specific regions of the PAD will be analyzed to automatically determine the test result. This removes human subjectivity in color interpretation. However, PAD images may be captured under different ambient lighting conditions and their global effect on PAD color distributions must be suppressed. Thus, it is important to perform color calibration using the color calibration zone on the PAD, which consists of different colored sub-regions, including a white region and a black region. Image analysis software can be used to compare the extracted colors in the PAD image's color calibration zone to known values to identify the specific color correction methods needed. One such method is white balancing, in which the overall brightness of the image is adjusted to force the white square in the PAD image to have a pure white color value. The calibration zone can be in any suitable shape, including rectangles, squares, circles, or triangles. The sub-regions can be in any suitable shape, including rectangles, squares, circles or triangles. Preferably, the color calibration zone is a rectangle region and the sub-regions are different colored squares. The color calibration zone can be printed onto the PAD prior to or after application of hydrophobic regions. The calibration zone can be placed anywhere on the PAD. Preferably, the calibration zone is printed on the PAD prior to application of hydrophobic regions and is located on an upper corner of the PAD.
  • In the preferred embodiment, the PAD of the invention comprises one information zone having a color calibration zone, another information zone having multiple fiducial marks, and yet another information zone comprising a QR code or other identification tag.
  • The method further comprises providing a camera device, capturing an image of the PAD that has reacted with the composition using the camera device, and providing an image analysis software capable of using information provided by the information zone and the image of the test result in order to identify and quantify a colorimetric change within the assay region of the paper analytical device shown in the captured image. In the preferred embodiment of the method of the invention, the capture image contains a two-dimensional bar code such as a QR code and one or more fiducial markers. The image software identifies the QR code region, separates the image of the PAD's assay regions from background present in the picture, scales, rotates, and performs geometrical transformations on the captured PAD image based on the QR code and the one or more fiducial markers, aligns the PAD assay regions with stored images in the database, reads test results from pre-specified locations in the stored assay regions, and classifies the test results. The method of the invention further comprises compiling a database of the captured images of the paper analytical devices and the computed test outcomes, wherein the two-dimensional barcode is a QR code that allows for automated identification of a specific PAD including the PAD-type, serial number and fabrication date.
  • In one embodiment, the image analysis software is provided on the camera device for processing the captured image in situ. Alternatively, the image analysis software may be provided on a network server such that the captured image is processed by sending the picture to the network server that performs the analysis and transmits the results back to the camera device.
  • Controls
  • The hydrophobic regions can also define control regions within the hydrophilic paper medium. For example, a timer region may be included in order to alert the user when the test has completed. The time region may comprise a colorimetric indicator. Additionally, the PAD may include positive or negative control regions. A negative control may be included in order to verify the purity of the reaction solvent. A positive control may be included in order to verify the presence (or absence) of the chemical to be detected. The control substrates, if any, may be included in the paper medium at the time the other colorimetric reagents are added to the paper medium. The PAD may also contain hydrophilic regions for titrations and/or reverse titrations, as well as user compliance lanes for improving the accuracy of the quantitative analysis of the chemicals.
  • Kits
  • The PADs may be packaged in kits providing a user with all of the materials necessary for using the PAD. For example, the kit may contain a solvent (such as deionized water or ethanol), a plastic micropipette, weighing paper, and a cotton swab. Instructions may be provided in hard copy, accessible via a link to a website or mobile application, accessible via a QR code or any combination thereof (including any equivalent and complementary instruction formats). The PADs comprising test reagents may be subjected to degradation due to temperature, light, or moisture which may affect the accuracy of the tests performed. As a result, the PADs may be individually packaged and sealed in light- and moisture-resistant packets. Additionally, the packets may be packaged with a desiccant in order to maintain a specific moisture level, and remove excess moisture. Another embodiment of the invention is a kit for detecting the presence/absence of a chemical and/or a chemical functional group in a composition, quantifying a chemical in a composition, or measuring the relative amounts of two materials present in a composition. Typically, the kit includes a PAD as disclosed herein; a solvent sufficient to saturate the paper assay device; and instructions for detecting the presence/absence of a chemical and/or a chemical functional group in a composition, quantifying a chemical in a composition, or measuring the relative amounts of two materials present in a composition. Preferably, the solvent is one that is sufficient to dissolve or suspend the composition containing the chemical and/or the chemical functional group to be analyzed. Typically, the kit contains a dish to hold the solvent and a spatula swab, or pipette for applying the composition onto the PAD.
  • The exemplary “cut and paste” devices 10 and 10′ described hereinabove are conducive for use with a variety of PAD embodiments in a kit. FIG. 4, for example, shows an exemplary embodiment of an Erythromycin PAD 30 comprising a color calibration zone 32, an identification zone 34, reaction areas as well as a timer region. PAD 30 includes a “red flag” wheel 36 having a plurality of spokes 36 a wherein each spoke is customizable with different chemicals to test for unique excipients and counterfeiting agents. The specific type of chemical in each spoke can be selected depending upon where the test is being conducted as well as to anticipate the types of counterfeit drugs that may be in use in such areas. If a spoke turns a different color when activated, such color change is indicative of the presence of a counterfeiting agent. Reaction areas 38, 40, 42, 44, 46 and 48 work in concert to perform a quantitative and qualitative assessment of the active ingredient and possible counterfeiting agents. In an exemplary PAD 30, HCl and Bromocresol green at area 38 works in conjunction with HCl and Methyl yellow at area 40 to help determine the concentration of Erythromycin. Ninhydrin at area 42 detects counterfeiting agents with primary or secondary amines. Sodium nitroprusside-acetylaldehyde at area 44 detects the presence of amines and counterfeiting agents. At area 46, phenol treated paper over a capillary containing sulfuric acid detects and differentiates between certain reducing sugars when activated colorimetrically. At area 48, ferric iron in glacial acetic acid and concentrated sulfuric acid, contained in a glass capillary under glass fiber paper, detects the presence of macrolide rings when activated. It is understood that testing is not constrained by the examples disclosed herein. For instance, wheel 36 and spokes 36 a thereof may be customizable along with the reaction areas to proactively combat changes in counterfeiting efforts. As counterfeiters recognize the testing patters of a PAD 30 and alter their products according, PAD 30 can be customized with alternative testing reagents in anticipation of the alteration of counterfeit products.
  • Lastly, the color changes of the PAD regions of interest are identified to determine a qualitative or qualitative test result. While the precise amount of active agent may not be identified, the brightness or intensity of the assaying region can provide some indication of the relative amount of active agent that is present in the product tested.
  • Example
  • An illustration of the invention and a comparison of its advantages over other devices appears below.
  • The Problem:
  • During the development of the Erythromycin PAD, it became necessary to create a new method for PAD fabrication. The paper had to be unadulterated, and the PAD had to be compatible with organic solvents. It was also necessary to develop a method of stabilizing certain reagents for long term storage. To this end, the Cut & Paste/Capillary Method was developed.
  • The PADs are developed as business-card sized testing systems that can help determine the authenticity of a suspicious pharmaceutical. Paper, or another absorbant material, is impregnated with a colorimetric reagent(s) that will indicate when a particular chemical or functional group is present.
  • The assay regions of the PAD were produced in a number of ways that are known to one skilled in the art:
  • SU-8 Method:
  • The paper medium is saturated with a crosslinking photoresist and then exposed to UV radiation in a pattern, creating hydrophobic and hydrophilic zones thereby.
  • Wax Method:
  • A modified inkjet printer places hydrophobic barriers of black wax to create lanes. The PAD is then heated to ensure full permeation through the paper.
  • Cut & Paste/Capillary Method:
  • The multilayer cut and paste design uses parafilm to attach unadulterated test strips to a laminate backing (e.g., as shown and described herein with respect to FIG. 1). Capillaries are loaded with unstable or corrosive reagents that are built into the PAD so that they can be broken on-site to release the reagent (e.g., as shown and described herein with respect to FIGS. 3 and 3A).
  • Cost Comparison:
  • Cost of reagents and labor were assumed to be approximately equal and therefore ignored for the purposes of this analysis.
  • TABLE 1
    SU-8:
    Paper: $0.07 per PAD (4,800 PADs per 100 sheet pack - $290.00)
    SU-8 photo resist: $1.315 per PAD
    Total: $1.36 per PAD
    Wax:
    Paper: $0.09 per PAD (3,200 PADs per 100 sheet pack - $290.00)
    Monochrome Wax Printing: $0.03 per PAD
    Total: $0.12 per PAD
    Cut & Paste:
    Paper: $0.013 per PAD (18,728 PADs per 100 sheet pack - $290.00)
    Laminate: $0.032 per PAD (450 PADS per 50 sheet pack - $14.85)
    Printer Paper: $0.002 per PAD (4,500 PADs per 500 sheets pack - $10.00)
    Parafilm: $0.034 per PAD (2,602 PADs per 250′ × 4″ pack - $89.10)
    Total: $0.08 per PAD
  • TABLE 2
    Observed Assets and Limitations
    SU-8 Wax Cut & Paste/Capillary
    ASSETS Precise lane Somewhat Very versatile
    control bio-
    degradable
    Rigid Unadult- Can use multiple types
    erated of absorbant material
    paper
    Insensitive to Precise lane control
    most temperature
    conditions
    Unadulterated paper
    Rigid
    Can be easily scaled up
    Needs less packaging
    Insensitive to most
    temperature conditions
    Lowest cost
    LIMITA- Cannot be used for Cannot use Not biodegradable
    TIONS acid sensitive organic
    analytes solvents
    One type of paper One type More involved
    of paper fabrication method
    Not biodegradable Lack of
    precise
    lane control
    Adulterated paper Not rigid
    (“floppy”)
    More involved Needs
    fabrication method significant
    packaging
    More difficult to Sensitive to
    scale up very warm
    temperature
    conditions
    Needs significant
    packaging
    Relatively higher
    cost
  • For the sake of brevity, it should be understood that certain structures and functionality, or aspects thereof, of embodiments of the presently disclosed invention that are evident from the illustrations of the figures have not been necessarily restated herein. Also, additional features relating to the use of the present invention can be found in U.S. patent application Ser. No. 13/566,915, filed Aug. 3, 2012, the entire disclosure of which is expressly incorporated herein by reference herein.
  • It is to be understood that the presently disclosed invention is not to be limited to the exact configurations as illustrated and described herein. To those of ordinary skill in the art, one or more inventions will be understood to be contemplated from the present application. Accordingly, all expedient modifications readily attainable by one of ordinary skill in the art from the disclosure set forth herein, or by routine experimentation there from, are deemed to be within the spirit and scope of the invention as defined by the appended claims.

Claims (16)

What is claimed is:
1. A multilayer Paper Analytical Device for detection of at least two chemical components indicative of a low quality pharmaceutical product or dietary supplement, comprising:
one or more assay regions in communication with a non-chemically interfering binder agent disposed adjacent at least one hydrophobic layer; and
one or more vessels each having a wall that houses one or more reagents in registry with at least one assay region for which testing for a chemical component is desired;
wherein rupture of a vessel wall establishes communication between a corresponding assay region and the one or more reagents released by the ruptured vessel wall.
2. The device of claim 1, wherein the at least one vessel is fabricated from a rupturable material.
3. The device of claim 1, wherein the one or more vessels are integral with at least assay region.
4. The device of claim 1, wherein the one or more vessels when ruptured are in fluid communication with the assay region.
5. The device of claim 1, wherein at least one or more of an information identification zone and a color calibration zone is provided on the Paper Analytic Device.
6. The device of claim 1, further comprising at least one electronically readable information zone that, after activation of the device, provides color information necessary for detection of the at least two chemical components, and wherein the least one electronically readable information zone comprises alignment references for transforming or correcting a captured image of the Paper Analytical Device to facilitate analysis and processing of the color information to more accurately detect the at least two chemical components.
7. The device of claim 6, wherein the alignment references include a plurality of fiducial markers for orienting the captured image.
8. The device of claim 6, wherein the hydrophilic substrate includes one or more user compliance or quality control regions.
9. The device of claim 6, wherein the chemical components to be detected include an active ingredient and an excipient, wherein the active ingredient includes at least one of a pharmaceutical or dietary supplement compound and wherein the color information determines whether an inappropriate combination of active ingredient and excipient is present, indicative of a low quality pharmaceutical or dietary supplement product.
10. A method for detection of at least two chemical components indicative of a low quality pharmaceutical or dietary supplement product, which comprises:
providing a multilayer analytical device according to claim 1;
disposing the pharmaceutical product to be analyzed into assay regions;
activating the device in a manner such that the reagents contact the product to be analyzed in the assay regions to provide color information; and
analyzing the color information to detect the presence or absence of the at least two chemical components.
11. The method of claim 10, wherein the pharmaceutical or dietary supplement product to be analyzed is disposed upon the assay regions by depositing the product onto the device or by applying a dilution containing the product onto the device;
wherein the activating of the device includes rupturing of the vessel wall sufficiently to enable release of the reagents therein to establish communication with the assay regions; and
wherein disposing the product into the assay region and activating the device cause a color change that can be analyzed to detect the presence or absence of the chemical components in the product.
12. The method of claim 10, wherein the device further includes a color calibration zone and the method further comprises automating the color analyzing by:
capturing an image of the device using a camera device; and
providing image analysis software capable of recognizing and quantifying a color change within the assay regions of the device that is shown in the captured image.
13. The method of claim 12, which further comprises:
repeating the detection for a plurality of pharmaceutical and dietary supplement products; and
compiling a database of the captured images of the analytical devices, including time stamping and geo-tagging of the captured images.
14. The method of claim 10, wherein the chemical components to be detected include an active ingredient and an excipient, and:
the presence of one of the chemical components determines that the pharmaceutical or dietary supplement product contains an insufficient amount of active ingredient;
the absence of one of the chemical components determines that the product does not contain an appropriate active ingredient;
the absence of one of the chemical components determines that the product does not contain an appropriate excipient; or
the presence of one of the chemical components determines that the product contains an inappropriate excipient.
15. The method of claim 10, wherein the chemical components to be detected include an active ingredient and an excipient, wherein the active ingredient includes at least one of an anti-malarial, antibiotic, anti-parasitic, cox-inhibitor, analgesic, antipyretic, anti-viral, anti-cancer and dietary supplement compound and wherein the color information determines whether an inappropriate combination of active ingredient and excipient is present, indicative of a low quality pharmaceutical or dietary supplement product.
16. A kit for detection of at least two chemical components indicative of a low quality pharmaceutical or dietary supplement product, the kit comprising:
a multilayer analytical device according to claim 1;
instructions for using the kit; and
a solvent that is present in an amount sufficient to dilute the product to be analyzed to an analyzable concentration.
US13/829,753 2012-08-17 2013-03-14 Analytical devices for detection of low-quality pharmaceuticals Active 2035-05-23 US9557274B2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US13/829,753 US9557274B2 (en) 2012-08-17 2013-03-14 Analytical devices for detection of low-quality pharmaceuticals
US15/254,186 US10119981B2 (en) 2012-08-17 2016-09-01 Analytical devices for detection of low-quality pharmaceuticals

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261684570P 2012-08-17 2012-08-17
US13/829,753 US9557274B2 (en) 2012-08-17 2013-03-14 Analytical devices for detection of low-quality pharmaceuticals

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US15/254,186 Continuation-In-Part US10119981B2 (en) 2012-08-17 2016-09-01 Analytical devices for detection of low-quality pharmaceuticals

Publications (2)

Publication Number Publication Date
US20140051173A1 true US20140051173A1 (en) 2014-02-20
US9557274B2 US9557274B2 (en) 2017-01-31

Family

ID=50100304

Family Applications (1)

Application Number Title Priority Date Filing Date
US13/829,753 Active 2035-05-23 US9557274B2 (en) 2012-08-17 2013-03-14 Analytical devices for detection of low-quality pharmaceuticals

Country Status (1)

Country Link
US (1) US9557274B2 (en)

Cited By (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2990118A1 (en) * 2014-08-25 2016-03-02 Xerox Corporation Design of paper sensor
US20160125600A1 (en) * 2014-11-04 2016-05-05 Samsung Electronics Co., Ltd. Method of and apparatus for measuring biometric information
KR20160052442A (en) * 2014-11-04 2016-05-12 삼성전자주식회사 Method and apparatus for measuring biometric information
WO2017140686A1 (en) * 2016-02-17 2017-08-24 Axagarius Gmbh & Co. Kg Measuring system for colorimetric assays
WO2018089315A1 (en) * 2016-11-08 2018-05-17 Reliant Immune Diagnostics, LLC System and method for image analysis of medical test results
US10024834B2 (en) * 2016-10-21 2018-07-17 Trace Eye-D, Llc Devices and methods for detecting an explosive substance
US10031120B2 (en) * 2016-10-21 2018-07-24 Trace Eye-D, Llc Devices and methods for detecting an explosive substance
US10274433B1 (en) * 2015-09-30 2019-04-30 Vium, Inc. Device and method of measuring animal health
US10331924B2 (en) 2016-12-14 2019-06-25 Reliant Immune Diagnostics, Inc. System and method for audiovisual response to retail diagnostic product
US10473659B2 (en) 2016-10-17 2019-11-12 Reliant Immune Diagnostics, Inc. System and method for immediate health assessment response system
US10527555B2 (en) 2016-12-14 2020-01-07 Reliant Immune Disgnostics, Inc. System and method for visual trigger to perform diagnostic test
US10631031B2 (en) 2016-12-14 2020-04-21 Reliant Immune Diagnostics, Inc. System and method for television network in response to input
US10636527B2 (en) 2018-06-06 2020-04-28 Reliant Immune Diagnostics, Inc. System and method for quantifying, ensuring, and triggering the prescriptive authority for a telemedicine session
US10902951B2 (en) 2016-10-17 2021-01-26 Reliant Immune Diagnostics, Inc. System and method for machine learning application for providing medical test results using visual indicia
US10930381B2 (en) 2017-11-10 2021-02-23 Reliant Immune Diagnostics, Inc. Microfluidic testing system for mobile veterinary applications
US10930380B2 (en) 2017-11-10 2021-02-23 Reliant Immune Diagnostics, Inc. Communication loop and record loop system for parallel/serial dual microfluidic chip
DE102019123474A1 (en) * 2019-09-02 2021-03-04 Testo SE & Co. KGaA Method for evaluating a color indicator
US11041185B2 (en) 2017-11-10 2021-06-22 Reliant Immune Diagnostics, Inc. Modular parallel/serial dual microfluidic chip
US11107585B2 (en) 2016-10-17 2021-08-31 Reliant Immune Diagnostics, Inc System and method for a digital consumer medical wallet and storehouse
US20210272330A1 (en) * 2014-03-31 2021-09-02 Healthy.Io Ltd. Methods and apparatus for enhancing color vision and quantifying color interpretation
US11112406B2 (en) 2018-06-15 2021-09-07 Reliant Immune Diagnostics, Inc. System and method for digital remote primary, secondary, and tertiary color calibration via smart device in analysis of medical test results
US11125749B2 (en) 2018-06-06 2021-09-21 Reliant Immune Diagnostics, Inc. System and method for remote colorimetry and ratiometric comparison and quantification in analysis of medical test results
US11124821B2 (en) 2017-11-10 2021-09-21 Reliant Immune Diagnostics, Inc. Microfluidic testing system with cell capture/analysis regions for processing in a parallel and serial manner
US11125746B2 (en) 2016-12-14 2021-09-21 Reliant Immune Diagnostics, Inc. Two-sided flow-through immunoassay
US11164680B2 (en) 2016-12-14 2021-11-02 Reliant Immune Diagnostics, Inc. System and method for initiating telemedicine conference using self-diagnostic test
US11170877B2 (en) 2016-12-14 2021-11-09 Reliant Immune Diagnostics, LLC System and method for correlating retail testing product to medical diagnostic code
US11200986B2 (en) 2017-11-10 2021-12-14 Reliant Immune Diagnostics, Inc. Database and machine learning in response to parallel serial dual microfluidic chip
US11232872B2 (en) 2018-06-06 2022-01-25 Reliant Immune Diagnostics, Inc. Code trigger telemedicine session
US11295859B2 (en) 2016-12-14 2022-04-05 Reliant Immune Diagnostics, Inc. System and method for handing diagnostic test results to telemedicine provider
US20220146408A1 (en) * 2017-02-17 2022-05-12 MFB Fertility, Inc. Method for detection and interpretation of results indicated on a photographed diagnostic test
US11397152B1 (en) 2015-09-30 2022-07-26 Recursion Pharmaceuticals, Inc. Device and method of measuring animal urine
US11437142B2 (en) 2017-11-10 2022-09-06 Reliant Immune Diagnostics, Inc. Biofluidic triggering system and method
US11527324B2 (en) 2017-11-10 2022-12-13 Reliant Immune Diagnostics, Inc. Artificial intelligence response system based on testing with parallel/serial dual microfluidic chip
US20230045755A1 (en) * 2020-04-22 2023-02-09 Paul J Gilbert Fluid characteristic indicator
US11579145B2 (en) 2016-10-17 2023-02-14 Reliant Immune Diagnostics, Inc. System and method for image analysis of medical test results
US11594337B2 (en) 2016-12-14 2023-02-28 Reliant Immune Diagnostics, Inc. System and method for advertising in response to diagnostic test results
US11599908B2 (en) 2016-12-14 2023-03-07 Reliant Immune Diagnostics, Inc. System and method for advertising in response to diagnostic test
US11651866B2 (en) 2016-10-17 2023-05-16 Reliant Immune Diagnostics, Inc. System and method for real-time insurance quote in response to a self-diagnostic test
WO2023096129A1 (en) * 2021-11-26 2023-06-01 주식회사 큐에스택 Image-based diagnosis system and control method therefor
US11693002B2 (en) 2016-10-17 2023-07-04 Reliant Immune Diagnostics, Inc. System and method for variable function mobile application for providing medical test results using visual indicia to determine medical test function type
US11802868B2 (en) 2016-10-17 2023-10-31 Reliant Immune Diagnostics, Inc. System and method for variable function mobile application for providing medical test results
US11915810B2 (en) 2016-12-14 2024-02-27 Reliant Immune Diagnostics, Inc. System and method for transmitting prescription to pharmacy using self-diagnostic test and telemedicine
US12009078B2 (en) 2016-10-17 2024-06-11 Reliant Immune Diagnostics, Inc. System and method for medical escalation and intervention that is a direct result of a remote diagnostic test

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9933359B2 (en) * 2014-06-23 2018-04-03 Xerox Corporation Vendor exclusivity security feature for paper-based diagnostic solution

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6136549A (en) 1999-10-15 2000-10-24 Feistel; Christopher C. systems and methods for performing magnetic chromatography assays
US6770487B2 (en) 2001-05-01 2004-08-03 Ischemia Technologies, Inc. Bar code readable diagnostic strip test
US6847451B2 (en) 2002-05-01 2005-01-25 Lifescan, Inc. Apparatuses and methods for analyte concentration determination
TWI340829B (en) 2002-12-27 2011-04-21 Transpacific Systems Llc Method for determining a response of each probe zone on a test strip
US7097103B2 (en) 2003-05-22 2006-08-29 Wen-Chao Tseng Method of automatically detecting a test result of a probe zone of a test strip
US7777287B2 (en) 2006-07-12 2010-08-17 Micron Technology, Inc. System and apparatus providing analytical device based on solid state image sensor
US8921118B2 (en) 2008-03-27 2014-12-30 President And Fellows Of Harvard College Paper-based microfluidic systems
US8206992B2 (en) 2008-03-27 2012-06-26 President And Fellows Of Harvard College Cotton thread as a low-cost multi-assay diagnostic platform
US8590791B2 (en) 2009-07-07 2013-11-26 Chemspectra, Inc. Color coded swipe for portable explosive or drug detection system

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
, Li et al., "A perspective on paper-based microfluidics: Current status and future trends", Biomicrofluidics, 2012, v. 6, pp. 011301-1-011301-13. *

Cited By (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210272330A1 (en) * 2014-03-31 2021-09-02 Healthy.Io Ltd. Methods and apparatus for enhancing color vision and quantifying color interpretation
RU2698818C2 (en) * 2014-08-25 2019-08-30 Зирокс Корпорейшн Paper sensitive element design
KR20160024780A (en) * 2014-08-25 2016-03-07 제록스 코포레이션 Design of paper sensor
CN105388143A (en) * 2014-08-25 2016-03-09 施乐公司 Design of paper sensor
KR102266347B1 (en) * 2014-08-25 2021-06-18 제록스 코포레이션 Design of paper sensor
EP2990118A1 (en) * 2014-08-25 2016-03-02 Xerox Corporation Design of paper sensor
KR102199462B1 (en) * 2014-11-04 2021-01-06 삼성전자주식회사 Method and apparatus for measuring biometric information
EP3018470A1 (en) * 2014-11-04 2016-05-11 Samsung Electronics Co., Ltd. Method of and apparatus for measuring biometric information
US20160125600A1 (en) * 2014-11-04 2016-05-05 Samsung Electronics Co., Ltd. Method of and apparatus for measuring biometric information
CN105572110A (en) * 2014-11-04 2016-05-11 三星电子株式会社 A method of and an apparatus for measuring biometric information
US10055837B2 (en) * 2014-11-04 2018-08-21 Samsung Electronics Co., Ltd. Method of and apparatus for measuring biometric information
KR20160052442A (en) * 2014-11-04 2016-05-12 삼성전자주식회사 Method and apparatus for measuring biometric information
US11397152B1 (en) 2015-09-30 2022-07-26 Recursion Pharmaceuticals, Inc. Device and method of measuring animal urine
US10274433B1 (en) * 2015-09-30 2019-04-30 Vium, Inc. Device and method of measuring animal health
WO2017140686A1 (en) * 2016-02-17 2017-08-24 Axagarius Gmbh & Co. Kg Measuring system for colorimetric assays
US11693002B2 (en) 2016-10-17 2023-07-04 Reliant Immune Diagnostics, Inc. System and method for variable function mobile application for providing medical test results using visual indicia to determine medical test function type
US11651866B2 (en) 2016-10-17 2023-05-16 Reliant Immune Diagnostics, Inc. System and method for real-time insurance quote in response to a self-diagnostic test
US11935657B2 (en) 2016-10-17 2024-03-19 Reliant Immune Diagnostics, Inc. System and method for a digital consumer medical wallet and storehouse
US11802868B2 (en) 2016-10-17 2023-10-31 Reliant Immune Diagnostics, Inc. System and method for variable function mobile application for providing medical test results
US12009078B2 (en) 2016-10-17 2024-06-11 Reliant Immune Diagnostics, Inc. System and method for medical escalation and intervention that is a direct result of a remote diagnostic test
US11107585B2 (en) 2016-10-17 2021-08-31 Reliant Immune Diagnostics, Inc System and method for a digital consumer medical wallet and storehouse
US11468991B2 (en) 2016-10-17 2022-10-11 Reliant Immune Diagnostics, Inc. System and method for machine learning application for providing medical test results using visual indicia
US10473659B2 (en) 2016-10-17 2019-11-12 Reliant Immune Diagnostics, Inc. System and method for immediate health assessment response system
US10902951B2 (en) 2016-10-17 2021-01-26 Reliant Immune Diagnostics, Inc. System and method for machine learning application for providing medical test results using visual indicia
US10928390B2 (en) 2016-10-17 2021-02-23 Reliant Immune Diagnostics, Inc. Medical apparatus for testing for medical conditions including zika and pregnancy
US11579145B2 (en) 2016-10-17 2023-02-14 Reliant Immune Diagnostics, Inc. System and method for image analysis of medical test results
US11567070B2 (en) 2016-10-17 2023-01-31 Reliant Immune Diagnostics, Inc. System and method for collection and dissemination of biologic sample test results data
US10031120B2 (en) * 2016-10-21 2018-07-24 Trace Eye-D, Llc Devices and methods for detecting an explosive substance
US10024834B2 (en) * 2016-10-21 2018-07-17 Trace Eye-D, Llc Devices and methods for detecting an explosive substance
US10746717B2 (en) * 2016-10-21 2020-08-18 Trace Eye-D, Llc Devices and methods for detecting an explosive substance
WO2018089315A1 (en) * 2016-11-08 2018-05-17 Reliant Immune Diagnostics, LLC System and method for image analysis of medical test results
US10527555B2 (en) 2016-12-14 2020-01-07 Reliant Immune Disgnostics, Inc. System and method for visual trigger to perform diagnostic test
US10331924B2 (en) 2016-12-14 2019-06-25 Reliant Immune Diagnostics, Inc. System and method for audiovisual response to retail diagnostic product
US11120235B2 (en) 2016-12-14 2021-09-14 Reliant Immune Diagnostics, Inc. System and method for audiovisual response to retail diagnostic product
US11594337B2 (en) 2016-12-14 2023-02-28 Reliant Immune Diagnostics, Inc. System and method for advertising in response to diagnostic test results
US11682207B2 (en) 2016-12-14 2023-06-20 Reliant Immune Diagnostics, Inc. System and method for audiovisual response to retail diagnostic product
US11125746B2 (en) 2016-12-14 2021-09-21 Reliant Immune Diagnostics, Inc. Two-sided flow-through immunoassay
US11164680B2 (en) 2016-12-14 2021-11-02 Reliant Immune Diagnostics, Inc. System and method for initiating telemedicine conference using self-diagnostic test
US11170877B2 (en) 2016-12-14 2021-11-09 Reliant Immune Diagnostics, LLC System and method for correlating retail testing product to medical diagnostic code
US11867635B2 (en) 2016-12-14 2024-01-09 Reliant Immune Diagnostics, Inc. System and method for visual trigger to perform diagnostic test
US11915810B2 (en) 2016-12-14 2024-02-27 Reliant Immune Diagnostics, Inc. System and method for transmitting prescription to pharmacy using self-diagnostic test and telemedicine
US11295859B2 (en) 2016-12-14 2022-04-05 Reliant Immune Diagnostics, Inc. System and method for handing diagnostic test results to telemedicine provider
US11599908B2 (en) 2016-12-14 2023-03-07 Reliant Immune Diagnostics, Inc. System and method for advertising in response to diagnostic test
US10890534B2 (en) 2016-12-14 2021-01-12 Reliant Immune Diagnostics, Inc. System and method for visual trigger to perform diagnostic test
US10635870B2 (en) 2016-12-14 2020-04-28 Reliant Immune Diagnostics, Inc. System and method for audiovisual response to retail diagnostic product
US10631031B2 (en) 2016-12-14 2020-04-21 Reliant Immune Diagnostics, Inc. System and method for television network in response to input
US20220146408A1 (en) * 2017-02-17 2022-05-12 MFB Fertility, Inc. Method for detection and interpretation of results indicated on a photographed diagnostic test
US12061196B2 (en) * 2017-02-17 2024-08-13 MFB Fertility, Inc. Method for detection and interpretation of results indicated on a photographed diagnostic test
US11437142B2 (en) 2017-11-10 2022-09-06 Reliant Immune Diagnostics, Inc. Biofluidic triggering system and method
US10930381B2 (en) 2017-11-10 2021-02-23 Reliant Immune Diagnostics, Inc. Microfluidic testing system for mobile veterinary applications
US11587658B2 (en) 2017-11-10 2023-02-21 Reliant Immune Diagnostics, Inc. Communication loop and record loop system for parallel/serial dual microfluidic chip
US10930380B2 (en) 2017-11-10 2021-02-23 Reliant Immune Diagnostics, Inc. Communication loop and record loop system for parallel/serial dual microfluidic chip
US11527324B2 (en) 2017-11-10 2022-12-13 Reliant Immune Diagnostics, Inc. Artificial intelligence response system based on testing with parallel/serial dual microfluidic chip
US11605450B2 (en) 2017-11-10 2023-03-14 Reliant Immune Diagnostics, Inc. Microfluidic testing system for mobile veterinary applications
US11041185B2 (en) 2017-11-10 2021-06-22 Reliant Immune Diagnostics, Inc. Modular parallel/serial dual microfluidic chip
US11200986B2 (en) 2017-11-10 2021-12-14 Reliant Immune Diagnostics, Inc. Database and machine learning in response to parallel serial dual microfluidic chip
US11124821B2 (en) 2017-11-10 2021-09-21 Reliant Immune Diagnostics, Inc. Microfluidic testing system with cell capture/analysis regions for processing in a parallel and serial manner
US11232872B2 (en) 2018-06-06 2022-01-25 Reliant Immune Diagnostics, Inc. Code trigger telemedicine session
US10636527B2 (en) 2018-06-06 2020-04-28 Reliant Immune Diagnostics, Inc. System and method for quantifying, ensuring, and triggering the prescriptive authority for a telemedicine session
US11125749B2 (en) 2018-06-06 2021-09-21 Reliant Immune Diagnostics, Inc. System and method for remote colorimetry and ratiometric comparison and quantification in analysis of medical test results
US11112406B2 (en) 2018-06-15 2021-09-07 Reliant Immune Diagnostics, Inc. System and method for digital remote primary, secondary, and tertiary color calibration via smart device in analysis of medical test results
US11836949B2 (en) 2019-09-02 2023-12-05 Testo SE & Co. KGaA Method for evaluating a color indicator
DE102019123474A1 (en) * 2019-09-02 2021-03-04 Testo SE & Co. KGaA Method for evaluating a color indicator
US20230045755A1 (en) * 2020-04-22 2023-02-09 Paul J Gilbert Fluid characteristic indicator
WO2023096129A1 (en) * 2021-11-26 2023-06-01 주식회사 큐에스택 Image-based diagnosis system and control method therefor

Also Published As

Publication number Publication date
US9557274B2 (en) 2017-01-31

Similar Documents

Publication Publication Date Title
US9557274B2 (en) Analytical devices for detection of low-quality pharmaceuticals
US20130034908A1 (en) Analytical devices for detection of low-quality pharmaceuticals
Noviana et al. Emerging applications of paper-based analytical devices for drug analysis: A review
US10119981B2 (en) Analytical devices for detection of low-quality pharmaceuticals
Sharifi et al. A 3D origami paper-based analytical device combined with PVC membrane for colorimetric assay of heavy metal ions: Application to determination of Cu (II) in water samples
US20150160245A1 (en) Ppm quantification of iodate using paper device
Luka et al. Portable device for the detection of colorimetric assays
EP3710810B1 (en) Sample carrier for optical measurements
Hiraoka et al. based device for naked eye urinary albumin/creatinine ratio evaluation
US10345244B2 (en) Diagnostic test device with patterned material spots
RU2728427C2 (en) Apparatus and system for collecting and analyzing steam condensate, in particular an exhaled air condensate, as well as a method for use thereof
Mathaweesansurn et al. Simple and fast fabrication of microfluidic paper-based analytical device by contact stamping for multiple-point standard addition assay: Application to direct analysis of urinary creatinine
CN101578520B (en) Based on formed pattern porous medium cross flow and through biometric apparatus, and preparation method thereof and using method
KR101954783B1 (en) Testing apparatus
CA2667702C (en) Lateral flow and flow-through bioassay devices based on patterned porous media, methods of making same, and methods of using same
US10486154B2 (en) Microfluidic device
Sharma et al. Advances in paper-analytical methods for pharmaceutical analysis
Ariza-Avidad et al. Printed disposable colorimetric array for metal ion discrimination
AU2003232337A1 (en) Fluorescence reference plate
Phadungcharoen et al. Smartphone-based Ellman’s colourimetric methods for the analysis of d-penicillamine formulation and thiolated polymer
Rahbar et al. High-throughput deposition of chemical reagents via pen-plotting technique for microfluidic paper-based analytical devices
Sruthi et al. Eco-friendly pH detecting paper-based analytical device: Towards process intensification
EP2905607A1 (en) Analyte detection methods and devices
CN102460127A (en) Device and method for the verification and quantitative analysis of analytes, particularly mycotoxins
JP2021128067A (en) Analysis device, analysis system, and analysis method

Legal Events

Date Code Title Description
AS Assignment

Owner name: ST. MARY'S COLLEGE, INDIANA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BARSTIS, TONI L.O.;BEVILAQUA, MARY M.;REEL/FRAME:030622/0823

Effective date: 20130313

AS Assignment

Owner name: ST. MARY'S COLLEGE, INDIANA

Free format text: CORRECTIVE ASSIGNMENT TO CORRECT THE MISSPELLING OF THE 2ND INVENTOR'S LAST NAME FROM "BEVILAQUA" TO --BEVILACQUA-- PREVIOUSLY RECORDED ON REEL 030622 FRAME 0823. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNOR'S INTEREST;ASSIGNORS:BARSTIS, TONI L.O.;BEVILACQUA, MARY M.;REEL/FRAME:036584/0912

Effective date: 20130313

STCF Information on status: patent grant

Free format text: PATENTED CASE

CC Certificate of correction
FEPP Fee payment procedure

Free format text: MAINTENANCE FEE REMINDER MAILED (ORIGINAL EVENT CODE: REM.); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY

FEPP Fee payment procedure

Free format text: SURCHARGE FOR LATE PAYMENT, SMALL ENTITY (ORIGINAL EVENT CODE: M2554); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY

MAFP Maintenance fee payment

Free format text: PAYMENT OF MAINTENANCE FEE, 4TH YR, SMALL ENTITY (ORIGINAL EVENT CODE: M2551); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY

Year of fee payment: 4

MAFP Maintenance fee payment

Free format text: PAYMENT OF MAINTENANCE FEE, 8TH YR, SMALL ENTITY (ORIGINAL EVENT CODE: M2552); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY

Year of fee payment: 8